A Drug Drug Interaction (DDI) Study of Selpercatinib (LY3527723) and Rosuvastatin in Healthy Participants
Status:
Not yet recruiting
Trial end date:
2023-10-10
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine the effect of selpercatinib on the levels of
rosuvastatin in the blood stream in healthy participants. This study will also evaluate the
safety and tolerability of rosuvastatin when administered in combination with selpercatinib
in healthy participants. This study will last up to approximately 26 days excluding screening
period.